← Leaderboards
Albert R La Spada
University Of Washington
$44,944,106
Attributed
$49,353,617
Total exposure
23
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,553,778 · 22
FDA$1,799,839 · 1
By mechanism
R01$33,457,407 · 11
RF1$6,020,481 · 2
R35$6,002,158 · 1
U01$1,584,955 · 1
P30$1,388,543 · 1
R21$830,379 · 2
Top collaborators
- Constanza Javiera Cortes4 shared
- William H Gerwick3 shared
- Vivian Y. H. Hook3 shared
- Virginia Eunice Kimonis3 shared
- Thomas E Lane3 shared
- Xiangmin Xu3 shared
- Jose Abdenur2 shared
- Elizabeth Carol Chao2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Gwenn A Garden$13,726,316
- Ryan James Carlson$39,876
Others in their field
Top investigators on “Neurodegenerative Disorders”
- Adam L Boxer · Mayo Clinic Rochester$61,054,677
- Paul S. Aisen · Cognition Therapeutics, Inc.$56,063,985
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$55,774,157
- Reisa A. Sperling · Banner Health$50,784,577
- Jane S Paulsen · University Of Wisconsin-Madison$38,012,377
- John Q. Trojanowski · University Of Pennsylvania$37,152,274
Research focus
Neurodegenerative DisordersPathway InteractionsPhenotypeProteinsMouse ModelPolyglutamineNerve DegenerationBaseMolecularNeuronsGene ExpressionGenesIn VivoTransgenic MicePathogenesisGenetic TranscriptionFundingNervous System DisorderRegulationNeurotoxicityInheritedMutantLinkCells
Grant awards (132)
MAP4K3 regulation of cellular stress response pathways in health and disease$1,310,665
RF1 · FY2025 · AG · contact PI
La Spada Outstanding Investigator Award$1,162,302
R35 · FY2025 · NS · contact PI
Southern California Undiagnosed Disease Network$767,099
U01 · FY2025 · NS
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$488,945
R01 · FY2025 · EY · contact PI
Summer Mentoring and Research Training in Eye and Vision Research (SMART EVR)$36,221
T35 · FY2025 · EY
La Spada Outstanding Investigator Award$1,127,433
R35 · FY2024 · NS · contact PI
Southern California Undiagnosed Disease Network$817,856
U01 · FY2024 · NS
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$503,195
R01 · FY2024 · EY · contact PI
La Spada Outstanding Investigator Award$1,162,302
R35 · FY2023 · NS · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,924
R01 · FY2023 · FD
MAP4K3 regulation of cellular stress response pathways in health and disease$2,022,582
RF1 · FY2022 · AG · contact PI
La Spada Outstanding Investigator Award$1,162,302
R35 · FY2022 · NS · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,938
R01 · FY2022 · FD
La Spada Outstanding Investigator Award$392,411
R35 · FY2022 · NS · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$275,347
R01 · FY2022 · EY · contact PI
La Spada Outstanding Investigator Award$995,408
R35 · FY2021 · NS · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,977
R01 · FY2021 · FD
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$275,347
R01 · FY2021 · EY · contact PI
Enhanced skeletal muscle proteostasis as a determinant of CNS protein quality control and neural function in the aging brain$53,514
RF1 · FY2021 · AG
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$355,398
R01 · FY2020 · NS · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$291,758
R01 · FY2020 · NS · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$279,844
R01 · FY2020 · EY · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$203,087
R01 · FY2020 · NS · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$162,931
R01 · FY2020 · EY · contact PI
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$107,658
R01 · FY2020 · NS · contact PI
Ataxia Investigators Meeting 8: Leveraging Therapeutic Opportunity into Novel Treatment Paradigms$20,000
R13 · FY2020 · NS · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$494,845
R01 · FY2019 · NS · contact PI
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$463,113
R01 · FY2019 · NS · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$368,318
R01 · FY2019 · AG · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$367,132
R01 · FY2019 · EY · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$343,679
R01 · FY2019 · AG · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$66,319
R01 · FY2019 · EY · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$60,158
R01 · FY2019 · AG · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$491,771
R01 · FY2018 · NS · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$426,035
R01 · FY2018 · AG · contact PI
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$411,635
R01 · FY2018 · NS · contact PI
SCA7 neurodegeneration: Molecular epigenetic basis and therapy$382,038
R01 · FY2018 · EY · contact PI
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$45,737
R01 · FY2018 · NS · contact PI
Enhanced skeletal muscle proteostasis as a determinant of CNS protein quality control and neural function in the aging brain$1,851,791
RF1 · FY2017 · AG · contact PI
Enhanced skeletal muscle proteostasis as a determinant of CNS protein quality control and neural function in the aging brain$705,452
RF1 · FY2017 · AG
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$457,371
R01 · FY2017 · NS · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$412,722
R01 · FY2017 · AG · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$327,101
R01 · FY2017 · NS · contact PI
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease$251,085
R01 · FY2017 · EY · contact PI
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease$244,066
R01 · FY2017 · EY · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$149,302
R01 · FY2017 · NS · contact PI
Enhanced skeletal muscle proteostasis as a determinant of CNS protein quality control and neural function in the aging brain$76,477
RF1 · FY2017 · AG · contact PI
SCA7 neurodegeneration: molecular epigenetic basis and therapy development$538,508
R01 · FY2016 · EY · contact PI
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease$495,152
R01 · FY2016 · EY · contact PI
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy$476,403
R01 · FY2016 · NS · contact PI
The PPAR-delta pathway in neural function and Huntington's disease neuropathology$471,121
R01 · FY2016 · NS · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$412,722
R01 · FY2016 · AG · contact PI
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease$485,250
R01 · FY2015 · EY · contact PI
SCA7 neurodegeneration: molecular epigenetic basis and therapy development$480,628
R01 · FY2015 · EY · contact PI
Molecular genetic regulation of autophagy in health and neurodegenerative disease$412,722
R01 · FY2015 · AG · contact PI
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease$495,140
R01 · FY2014 · EY · contact PI
SCA7 neurodegeneration: molecular epigenetic basis and therapy development$480,489
R01 · FY2014 · EY · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$328,215
R01 · FY2014 · NS · contact PI
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$327,897
R01 · FY2014 · NS · contact PI
SCA7 neurodegeneration: molecular epigenetic basis and therapy development$551,981
R01 · FY2013 · EY · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR DEGENERATION$353,400
R01 · FY2013 · EY · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$319,928
R01 · FY2013 · NS · contact PI
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$319,617
R01 · FY2013 · NS · contact PI
Autophagy and protein translation in neural function & neurodegeneration$284,816
R01 · FY2013 · AG · contact PI
Antisense oligonucleotide knock-down of ataxin-7 in a SCA7 mouse model$186,969
R21 · FY2013 · NS · contact PI
CORE B: Genetics Core$183,030
P30 · FY2013 · HD · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR DEGENERATION$371,900
R01 · FY2012 · EY · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$331,531
R01 · FY2012 · NS · contact PI
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$331,209
R01 · FY2012 · NS · contact PI
CORE B: Genetics Core$321,703
P30 · FY2012 · HD · contact PI
Autophagy and protein translation in neural function & neurodegeneration$301,392
R01 · FY2012 · AG · contact PI
Neuronal RNA processing defects in ALS4 caused by SETX mutations$296,159
R01 · FY2012 · GM · contact PI
Antisense oligonucleotide knock-down of ataxin-7 in a SCA7 mouse model$232,500
R21 · FY2012 · NS · contact PI
Huntington's Disease Natural Product Drug Discovery$158,875
R21 · FY2012 · AG
ROLE OF Nna1 IN RETINAL AND CEREBELLAR DEGENERATION$77,500
R01 · FY2012 · EY · contact PI
Huntington's Disease Natural Product Drug Discovery$62,000
R21 · FY2012 · AG
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$50,000
R01 · FY2012 · NS · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR DEGENERATION$370,800
R01 · FY2011 · EY · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$331,531
R01 · FY2011 · NS · contact PI
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$331,209
R01 · FY2011 · NS · contact PI
CORE B: Genetics Core$320,340
P30 · FY2011 · HD · contact PI
Autophagy and protein translation in neural function & neurodegeneration$301,392
R01 · FY2011 · AG · contact PI
Neuronal RNA processing defects in ALS4 caused by SETX mutations$296,159
R01 · FY2011 · GM · contact PI
Huntington's Disease Natural Product Drug Discovery$190,035
R21 · FY2011 · AG
MITOCHONDRIAL DYSFUNCTION IN NNAD MUTANT FLIES AND PURKINJE CELL DEGENERATION$6,458
P41 · FY2011 · RR · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$367,092
R01 · FY2010 · GM · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$350,219
R01 · FY2010 · NS · contact PI
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog$337,969
R01 · FY2010 · NS · contact PI
Autophagy and protein translation in neural function & neurodegeneration$313,558
R01 · FY2010 · AG · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR DEGENERATION$289,688
R01 · FY2010 · EY · contact PI
CORE B: Genetics Core$281,682
P30 · FY2010 · HD · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$154,525
R01 · FY2010 · GM · contact PI
MITOCHONDRIAL DYSFUNCTION IN NNAD MUTANT FLIES AND PURKINJE CELL DEGENERATION$1,445
P41 · FY2010 · RR · contact PI
SCA7 NEURODEGENERATION: MOLECULAR BASIS AND THERAPY$386,250
R01 · FY2009 · EY · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$357,425
R01 · FY2009 · GM · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$324,980
R01 · FY2009 · NS · contact PI
Autophagy and protein translation in neural function & neurodegeneration$316,725
R01 · FY2009 · AG · contact PI
CORE B: Genetics Core$281,788
P30 · FY2009 · HD · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$118,206
R01 · FY2009 · NS · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$7,761
R01 · FY2009 · GM · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$7,428
R01 · FY2009 · NS · contact PI
SCA7 NEURODEGENERATION: MOLECULAR BASIS AND THERAPY$382,200
R01 · FY2008 · EY · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$370,099
R01 · FY2008 · GM · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$332,409
R01 · FY2008 · NS · contact PI
Non-cell autonomous neurodegeneration in SCA7$312,000
R01 · FY2008 · NS
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$253,846
R01 · FY2008 · EY · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$34,682
R01 · FY2008 · EY · contact PI
SCA7 NEURODEGENERATION: MOLECULAR BASIS AND THERAPY$390,000
R01 · FY2007 · EY · contact PI
CCCTC-binding factor (CTCF) in trinucleotide repeat instability and disease$373,900
R01 · FY2007 · GM · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$332,409
R01 · FY2007 · NS · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$294,416
R01 · FY2007 · EY · contact PI
PROTEOMIC ANALYSIS OF FACTORS INVOLVED IN PCD PHENOTYPES$5,570
P41 · FY2007 · RR · contact PI
SCA7 RETINAL DEGENERATION: MOLECULAR BASIS & THERAPY$370,094
R01 · FY2006 · EY · contact PI
MODELS OF SBMA MOTOR NEURON DEGENERATION$342,337
R01 · FY2006 · NS · contact PI
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$296,075
R01 · FY2006 · EY · contact PI
SCA7 RETINAL DEGENERATION: MOLECULAR BASIS &THERAPY$379,000
R01 · FY2005 · EY
MODELS OF SBMA MOTOR NEURON DEGENERATION$350,575
R01 · FY2005 · NS
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$303,200
R01 · FY2005 · EY
SCA7 RETINAL DEGENERATION: MOLECULAR BASIS &THERAPY$379,000
R01 · FY2004 · EY
ROLE OF Nna1 IN RETINAL AND CEREBELLAR NEURODEGENERATION$303,200
R01 · FY2004 · EY
MODELS OF SBMA MOTOR NEURON DEGENERATION$227,400
R01 · FY2004 · NS
MODELS OF SBMA MOTOR NEURON DEGENERATION$75,800
R01 · FY2004 · NS
MOLECULAR BASIS OF TRINUCLEOTIDE REPEAT INSTABILITY$381,271
R01 · FY2003 · GM
SCA7 RETINAL DEGENERATION: MOLECULAR BASIS &THERAPY$379,000
R01 · FY2003 · EY
MODELS OF SBMA MOTOR NEURON DEGENERATION$227,400
R01 · FY2003 · NS
MODELS OF SBMA MOTOR NEURON DEGENERATION$75,800
R01 · FY2003 · NS
SCA7 RETINAL DEGENERATION: MOLECULAR BASIS &THERAPY$379,167
R01 · FY2002 · EY
MOLECULAR BASIS OF TRINUCLEOTIDE REPEAT INSTABILITY$370,255
R01 · FY2002 · GM
MODELS OF SBMA MOTOR NEURON DEGENERATION$227,450
R01 · FY2002 · NS
MOLECULAR BASIS OF TRINUCLEOTIDE REPEAT INSTABILITY$342,822
R01 · FY2001 · GM
MODELS OF SBMA MOTOR NEURON DEGENERATION$228,000
R01 · FY2001 · NS
MOLECULAR BASIS OF TRINUCLEOTIDE REPEAT INSTABILITY$281,227
R01 · FY2000 · GM